Borrow it
Coverart for item
The Resource Frontiers in clinical drug research, Volume 4, Alzheimer disorders, edited by Atta-ur-Rahman

Frontiers in clinical drug research, Volume 4, Alzheimer disorders, edited by Atta-ur-Rahman

Work
Publication
Extent
1 online resource.
Contents
  • PREFACE ; List of Contributors ; Melatoninergic Pathways in Alzheimer's Disease ; 1. INTRODUCTION; 2. ALZHEIMER'S DISEASE OVERVIEW; 2.1. Classical Alzheimer's Disease Pathophysiology; 2.2. Systemic Immune Inflammation and AD; 2.3. Oxidative and Nitrosative Stress, Cytokines and Tryptophan Catabolites; 2.4. Oxidative and Nitrosative Stress and Cellular Damage; 2.5. ApoE4; 2.6. Immuno-Senescence and Alzheimer's Disease; 2.7. Circadian Rhythms and Alzheimer's Disease; 2.8. Conclusions on Alzheimer's Disease Processes; 3. MELATONINERGIC PATHWAYS OVERVIEW; 3.1. Immune-Pineal Axis
  • 4. ALZHEIMER'S DISEASE: MELATONIN AND NAS4.1. Melatonin and AD; 4.2. Melatonin and AD Models; 4.3. Melatonin in AD Treatment ; 4.4. Alzheimer's Disease: Local Melatonin And NAS ; 4.5. Other Potential Local Melatonin Regulators; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Pharmaceutical and Nutritional Benefits in Alzheimer's Disease via Convergence on the Melatoninergic Pathways ; 1. INTRODUCTION; 1.1. Methods; 2. PHARMACOLOGICAL AND DIETARY TREATMENTS; 2.1. Overview; 2.1.1. Serotonin, Tryptophan and SSRIs; 2.1.2. Monoamine Oxidase Inhibitors
  • CONFLICTS OF INTERESTACKNOWLEDGEMENTS; REFERENCES; Some Questions Posed About the Prevention and Treatment of Alzheimer's Disease ; INTRODUCTION; 1. WHAT IS THE NEED FOR PREVENTION AND TREATMENT OF AD?; 2. DOES IT MAKE SENSE TO SEPARATE PREVENTION AND TREATMENT OF AD?; 3. DO WE KNOW ENOUGH ABOUT THE AETIOLOGY AND PATHOGENESIS OF AD TO BE ABLE TO PREVENT OR TREAT IT?; 4. SHOULD A-BETA42 BE THE MAIN THERAPEUTIC TARGET FOR TREATMENT STRATEGIES IN AD?; 5. WHY IS DIAGNOSIS IMPORTANT IN PREVENTING AND TREATING AD?
Isbn
9781681081472
Instance
Label
Frontiers in clinical drug research, Volume 4, Alzheimer disorders
Title
Frontiers in clinical drug research
Title number
Volume 4
Title part
Alzheimer disorders
Statement of responsibility
edited by Atta-ur-Rahman
Contributor
Editor
Subject
Genre
Language
eng
Cataloging source
YDXCP
Dewey number
616.8311
Index
index present
LC call number
RC523*
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorDate
1942-
http://library.link/vocab/relatedWorkOrContributorName
Rahman, Atta-ur-
http://library.link/vocab/subjectName
  • Alzheimer's disease
  • Senile dementia
  • Pharmacology
  • Drugs
  • HEALTH & FITNESS / Diseases / General
  • MEDICAL / Clinical Medicine
  • MEDICAL / Diseases
  • MEDICAL / Evidence-Based Medicine
  • MEDICAL / Internal Medicine
  • Alzheimer's disease
  • Drugs
  • Pharmacology
  • Senile dementia
Label
Frontiers in clinical drug research, Volume 4, Alzheimer disorders, edited by Atta-ur-Rahman
Instantiates
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • PREFACE ; List of Contributors ; Melatoninergic Pathways in Alzheimer's Disease ; 1. INTRODUCTION; 2. ALZHEIMER'S DISEASE OVERVIEW; 2.1. Classical Alzheimer's Disease Pathophysiology; 2.2. Systemic Immune Inflammation and AD; 2.3. Oxidative and Nitrosative Stress, Cytokines and Tryptophan Catabolites; 2.4. Oxidative and Nitrosative Stress and Cellular Damage; 2.5. ApoE4; 2.6. Immuno-Senescence and Alzheimer's Disease; 2.7. Circadian Rhythms and Alzheimer's Disease; 2.8. Conclusions on Alzheimer's Disease Processes; 3. MELATONINERGIC PATHWAYS OVERVIEW; 3.1. Immune-Pineal Axis
  • 4. ALZHEIMER'S DISEASE: MELATONIN AND NAS4.1. Melatonin and AD; 4.2. Melatonin and AD Models; 4.3. Melatonin in AD Treatment ; 4.4. Alzheimer's Disease: Local Melatonin And NAS ; 4.5. Other Potential Local Melatonin Regulators; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Pharmaceutical and Nutritional Benefits in Alzheimer's Disease via Convergence on the Melatoninergic Pathways ; 1. INTRODUCTION; 1.1. Methods; 2. PHARMACOLOGICAL AND DIETARY TREATMENTS; 2.1. Overview; 2.1.1. Serotonin, Tryptophan and SSRIs; 2.1.2. Monoamine Oxidase Inhibitors
  • CONFLICTS OF INTERESTACKNOWLEDGEMENTS; REFERENCES; Some Questions Posed About the Prevention and Treatment of Alzheimer's Disease ; INTRODUCTION; 1. WHAT IS THE NEED FOR PREVENTION AND TREATMENT OF AD?; 2. DOES IT MAKE SENSE TO SEPARATE PREVENTION AND TREATMENT OF AD?; 3. DO WE KNOW ENOUGH ABOUT THE AETIOLOGY AND PATHOGENESIS OF AD TO BE ABLE TO PREVENT OR TREAT IT?; 4. SHOULD A-BETA42 BE THE MAIN THERAPEUTIC TARGET FOR TREATMENT STRATEGIES IN AD?; 5. WHY IS DIAGNOSIS IMPORTANT IN PREVENTING AND TREATING AD?
Control code
932263771
Dimensions
unknown
Extent
1 online resource.
File format
unknown
Form of item
online
Isbn
9781681081472
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)932263771
Label
Frontiers in clinical drug research, Volume 4, Alzheimer disorders, edited by Atta-ur-Rahman
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • PREFACE ; List of Contributors ; Melatoninergic Pathways in Alzheimer's Disease ; 1. INTRODUCTION; 2. ALZHEIMER'S DISEASE OVERVIEW; 2.1. Classical Alzheimer's Disease Pathophysiology; 2.2. Systemic Immune Inflammation and AD; 2.3. Oxidative and Nitrosative Stress, Cytokines and Tryptophan Catabolites; 2.4. Oxidative and Nitrosative Stress and Cellular Damage; 2.5. ApoE4; 2.6. Immuno-Senescence and Alzheimer's Disease; 2.7. Circadian Rhythms and Alzheimer's Disease; 2.8. Conclusions on Alzheimer's Disease Processes; 3. MELATONINERGIC PATHWAYS OVERVIEW; 3.1. Immune-Pineal Axis
  • 4. ALZHEIMER'S DISEASE: MELATONIN AND NAS4.1. Melatonin and AD; 4.2. Melatonin and AD Models; 4.3. Melatonin in AD Treatment ; 4.4. Alzheimer's Disease: Local Melatonin And NAS ; 4.5. Other Potential Local Melatonin Regulators; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Pharmaceutical and Nutritional Benefits in Alzheimer's Disease via Convergence on the Melatoninergic Pathways ; 1. INTRODUCTION; 1.1. Methods; 2. PHARMACOLOGICAL AND DIETARY TREATMENTS; 2.1. Overview; 2.1.1. Serotonin, Tryptophan and SSRIs; 2.1.2. Monoamine Oxidase Inhibitors
  • CONFLICTS OF INTERESTACKNOWLEDGEMENTS; REFERENCES; Some Questions Posed About the Prevention and Treatment of Alzheimer's Disease ; INTRODUCTION; 1. WHAT IS THE NEED FOR PREVENTION AND TREATMENT OF AD?; 2. DOES IT MAKE SENSE TO SEPARATE PREVENTION AND TREATMENT OF AD?; 3. DO WE KNOW ENOUGH ABOUT THE AETIOLOGY AND PATHOGENESIS OF AD TO BE ABLE TO PREVENT OR TREAT IT?; 4. SHOULD A-BETA42 BE THE MAIN THERAPEUTIC TARGET FOR TREATMENT STRATEGIES IN AD?; 5. WHY IS DIAGNOSIS IMPORTANT IN PREVENTING AND TREATING AD?
Control code
932263771
Dimensions
unknown
Extent
1 online resource.
File format
unknown
Form of item
online
Isbn
9781681081472
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)932263771

Subject

Genre

Library Locations

    • Thomas Jefferson LibraryBorrow it
      1 University Blvd, St. Louis, MO, 63121, US
      38.710138 -90.311107

Library Links

Structured data from the Bibframe namespace is licensed under the Creative Commons Attribution 4.0 International License by University of Missouri-St. Louis Libraries. Additional terms may apply to data associated with third party namespaces.
Processing Feedback ...